Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Lumacaftor/Ivacaftor in Cystic Fibrosis
NCT02544451Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2015; status: completed.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02544451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544451.